Related Experiment Video
Updated: Oct 5, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
ACEI/ARB Medication During ICU Stay Decrease All-Cause In-hospital Mortality in Critically Ill Patients With
Boshen Yang1, Sixuan Xu2, Di Wang1
1Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Insights
Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (ACEI/ARB) use in critically ill hypertensive patients was associated with significantly lower in-hospital mortality. This finding highlights the potential survival benefit of ACEI/ARB medications in this vulnerable patient population.
Area of Science:
- Critical Care Medicine
- Pharmacology
- Cardiovascular Disease
Background:
- Hypertension is a frequent comorbidity in critically ill patients.
- Critically ill patients with hypertension may experience higher hospital mortality.
- High blood pressure is defined as systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg.
Purpose of the Study:
- To investigate the association between the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) during intensive care unit (ICU) stay and all-cause in-hospital mortality.
- To explore the impact of ACEI/ARB medication on survival rates in critically ill patients with hypertension.
Main Methods:
- Retrospective cohort study using the Medical Information Mart for Intensive Care IV (MIMIC-IV) database (2008-2019).
- Inclusion criteria: adults with hypertension on admission or high blood pressure during ICU stay.
- Propensity score matching (PSM) and machine learning models (LightGBM) were employed to analyze associations and predict mortality, with SHAP values for feature importance.
Main Results:
- A total of 15,352 patients were analyzed, with 33.8% receiving ACEI/ARB.
- ACEI/ARB treatment was associated with significantly lower all-cause in-hospital mortality (3.9% vs. 12.7%) and 28-day mortality (3.6% vs. 12.2%).
- The LightGBM model demonstrated high predictive performance (AUC = 0.9935), with ACEI/ARB use identified as a key factor associated with reduced mortality.
Conclusions:
- ACEI/ARB use in critically ill hypertensive patients during ICU stay is linked to reduced all-cause in-hospital mortality.
- ACEI/ARB medication demonstrated an independent association with increased survival in a diverse group of critically ill hypertensive patients.
- These findings suggest a potential benefit of continuing or initiating ACEI/ARB therapy in managing hypertensive patients within the ICU setting.
Abstract:
Background: Hypertension is a rather common comorbidity among critically ill patients and hospital mortality might be higher among critically ill patients with hypertension (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg). This study aimed to explore the association between ACEI/ARB medication during ICU stay and all-cause in-hospital mortality in these patients. Methods: A retrospective cohort study was conducted based on data from Medical Information Mart for Intensive Care IV (MIMIC-IV) database, which consisted of more than 40,000 patients in ICU between 2008 and 2019 at Beth Israel Deaconess Medical Center. Adults diagnosed with hypertension on admission and those had high blood pressure (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg) during ICU stay were included. The primary outcome was all-cause in-hospital mortality. Patients were divided into ACEI/ARB treated and non-treated group during ICU stay. Propensity score matching (PSM) was used to adjust potential confounders. Nine machine learning models were developed and validated based on 37 clinical and laboratory features of all patients. The model with the best performance was selected based on area under the receiver operating characteristic curve (AUC) followed by 5-fold cross-validation. After hyperparameter optimization using Grid and random hyperparameter search, a final LightGBM model was developed, and Shapley Additive exPlanations (SHAP) values were calculated to evaluate feature importance of each feature. The features closely associated with hospital mortality were presented as significant features. Results: A total of 15,352 patients were enrolled in this study, among whom 5,193 (33.8%) patients were treated with ACEI/ARB. A significantly lower all-cause in-hospital mortality was observed among patients treated with ACEI/ARB (3.9 vs. 12.7%) as well as a lower 28-day mortality (3.6 vs. 12.2%). The outcome remained consistent after propensity score matching. Among nine machine learning models, the LightGBM model had the highest AUC = 0.9935. The SHAP plot was employed to make the model interpretable based on LightGBM model after hyperparameter optimization, showing that ACEI/ARB use was among the top five significant features, which were associated with hospital mortality. Conclusions: The use of ACEI/ARB in critically ill patients with hypertension during ICU stay is related to lower all-cause in-hospital mortality, which was independently associated with increased survival in a large and heterogeneous cohort of critically ill hypertensive patients with or without kidney dysfunction.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Acute Coronary Syndrome IV: Interprofessional Care
Heart Failure V: Medical Management
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Cardiopulmonary Resuscitation IV: Pharmacological Management

